SCHEMBL3267897

SCHEMBL3267897

COc1ccc(CCOc2cncc(Cl)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
P2RX7 Q99572 1/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALOX5 P09917 1/20 0.40
LMNA P02545 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39
HTR2B P41595 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
ADORA2A P29274 1/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1993092 0.85 PDE2A (0.47) MEN1KMT2AP2RX7ALDH1A1SMN1; SMN2
SCHEMBL3270815 0.84 TAAR1 (0.46) ALDH1A1LMNATAAR1HTR2CSLC6A4
SCHEMBL3266637 0.82 PLK1 (0.45) ALDH1A1SMN1; SMN2LMNAKDM4ERAB9A
SCHEMBL3266850 0.82 ELOVL1 (0.40) ALDH1A1HTR2CHTR2BCYP3A4CALM1
SCHEMBL3266762 0.80 CYP11B1 (0.47) PDGFRBPDGFRARAB9ACYP11B1CYP11B2
SCHEMBL3267977 0.79 CTRC (0.38) HTR2CHTR2BCYP1A2CYP2D6CYP2C9
SCHEMBL3268080 0.78 CYP11B2 (0.45) KDM4ERAB9ACYP11B1CYP11B2CYP1A2
SCHEMBL11374043 0.77 HTT (0.50) MEN1KMT2AALDH1A1LMNARAB9A
SCHEMBL3272705 0.75 CHRNA7 (0.44) CYP11B1CYP11B2CYP1A2CYP3A4CYP2D6
SCHEMBL3267252 0.75 PDE2A (0.45) MEN1KMT2AALDH1A1LMNATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335907-B1 PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR BIOVITRUM AB PUBL (SE) 2010-06-09 EP disclosed
US-7247633-B2 Pyrimidine compounds and their use BIOVITRUM AB (SE) 2007-07-24 US disclosed
US-20040014767-A1 Novel compounds and their use BIOVITRUM AB, A SWEDISH CORPORATION 2004-01-22 US disclosed
EP-1335907-A1 PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR BIOVITRUM AB (SE) 2003-08-20 EP disclosed
US-6593330-B2 Central nervous system disorders; antiserotonine agents BIOVITRUM (SE) 2003-07-15 US disclosed
US-20020147200-A1 Novel compounds and their use PROXIMAGEN NEUROSCIENCE PLC (GB) 2002-10-10 US disclosed
WO-2002040456-A1 PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR BIOVITRUM AB (SE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147200-A1 Novel compounds and their use BRIX1, UGT1A1, NR5A1 MEN1 633/4885KMT2A 1705/4885P2RX7 2052/4885
US-20040014767-A1 Novel compounds and their use BRIX1, UGT1A1, NR5A1 MEN1 633/4885KMT2A 1705/4885P2RX7 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.